Attention, memory and brain fog are not one interchangeable outcome. A person may use all three terms to describe difficulty functioning, but the underlying clinical question still needs to be defined. Evidence becomes misleading when a study of one process is promoted as proof that every cognitive complaint will improve.
A Selank cognition experiment studied rats whose catecholamine systems had been experimentally injured early in life. The reported behavioral findings are relevant to that model. They are not observations from adults with ADHD, and the induced injury should not be treated as a direct representation of every attention disorder.
A separate human functional-connectivity study assessed healthy participants after either Selank, Semax or placebo. It measured resting-state brain connectivity. The intervention groups were alternatives, not a test establishing the effectiveness of a Selank–Semax combination. A connectivity change also is not equivalent to improved work performance or a validated ADHD symptom response.
These distinctions do not make the experiments useless. Animal models can probe mechanisms, and imaging can identify biological signals worth following. Their value depends on preserving the endpoint rather than upgrading it to an unmeasured clinical benefit.
For a treatment claim, stronger evidence would connect a characterized intervention to meaningful changes in the relevant patient group. That would include an appropriate comparison, prespecified outcomes and sufficient follow-up to understand adverse effects and persistence. A personal account of improved concentration cannot provide all of those safeguards.
Persistent cognitive difficulties deserve clinical attention because the label brain fog does not identify a single cause. A clinician can consider the pattern of symptoms, sleep, mood, existing medicines and other relevant health factors. This article does not establish an alternative to diagnostic assessment or authorize changing prescribed ADHD treatment.
The evidence accessed here consists of primary abstracts. It supports a description of experimental cognitive and imaging research, not a conclusion that Selank is an established ADHD medicine or a general cognitive enhancer. The most useful next question is exactly which function needs improvement and what human evidence measures that function in a comparable population.